Clarius Group LLC Has $1.40 Million Stock Position in Axon Enterprise, Inc (NASDAQ:AXON)

Clarius Group LLC lifted its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 1.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,666 shares of the biotechnology company’s stock after purchasing an additional 33 shares during the period. Clarius Group LLC’s holdings in Axon Enterprise were worth $1,402,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Fourth Dimension Wealth LLC acquired a new position in Axon Enterprise during the fourth quarter worth approximately $30,000. Elequin Capital LP bought a new position in shares of Axon Enterprise during the 4th quarter worth approximately $46,000. CoreFirst Bank & Trust acquired a new position in shares of Axon Enterprise during the 4th quarter worth approximately $59,000. Global Financial Private Client LLC raised its stake in Axon Enterprise by 11,100.0% in the 1st quarter. Global Financial Private Client LLC now owns 112 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 111 shares during the period. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH bought a new stake in Axon Enterprise in the 1st quarter valued at $77,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $777.54 on Wednesday. The company has a current ratio of 2.83, a quick ratio of 2.62 and a debt-to-equity ratio of 0.68. The firm has a fifty day simple moving average of $679.36 and a two-hundred day simple moving average of $623.45. Axon Enterprise, Inc has a 12 month low of $279.02 and a 12 month high of $806.64. The firm has a market capitalization of $60.53 billion, a PE ratio of 187.81, a price-to-earnings-growth ratio of 89.86 and a beta of 1.29.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The business had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same quarter in the previous year, the business earned $1.15 EPS. The company’s quarterly revenue was up 31.3% on a year-over-year basis. Analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analyst Ratings Changes

AXON has been the subject of several research reports. Bank of America raised their price objective on shares of Axon Enterprise from $750.00 to $895.00 and gave the stock a “buy” rating in a research report on Wednesday, June 4th. Northcoast Research lowered Axon Enterprise from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 19th. Needham & Company LLC lifted their price target on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. Barclays upped their price objective on Axon Enterprise from $726.00 to $735.00 and gave the company an “overweight” rating in a report on Friday, May 9th. Finally, Craig Hallum downgraded Axon Enterprise from a “buy” rating to a “cautious” rating in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and a consensus price target of $699.55.

Insider Transactions at Axon Enterprise

In related news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the transaction, the chief executive officer now owns 3,063,982 shares in the company, valued at approximately $1,657,583,622.18. This represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, President Joshua Isner sold 9,905 shares of the business’s stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $738.03, for a total transaction of $7,310,187.15. Following the completion of the transaction, the president now owns 298,809 shares in the company, valued at approximately $220,530,006.27. The trade was a 3.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 43,737 shares of company stock worth $29,797,795 in the last 90 days. Insiders own 5.70% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.